Your browser doesn't support javascript.
Pityriasis Rosea Following Pfizer-BioNTech Vaccination in an Adolescent Girl.
Bin Rubaian, Nouf F; Almuhaidib, Seereen R; Aljarri, Shadan A; Alamri, Areen S.
  • Bin Rubaian NF; Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
  • Almuhaidib SR; Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
  • Aljarri SA; Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
  • Alamri AS; Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
Cureus ; 14(7): e27108, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1998012
ABSTRACT
Pityriasis rosea (PR) is an acute self-limiting exanthematous skin disorder characterized by the presence of a primary solitary lesion called a herald patch and the subsequent development of diffuse papulosquamous lesions within 1 to 2 weeks. This is a case of COVID-19 vaccine-induced PR in the age group (12-18 years) that was recently approved for vaccination. We report a case of a 15-year-old otherwise healthy female with a history of 2 weeks of single oval primary plaque appearing on the right wrist 2 days after receiving the second dose of Pfizer-BioNTech vaccine, followed by diffuse and mild itchy skin eruptions spreading over the abdomen, back, chest, and extremities. The patient had no other symptoms and no PR risk factors. The patient was placed on 800 mg acyclovir five times a day and improved markedly after 1 week. As vaccine-induced PR/PR-like eruptions (PR-LE) is an uncommon phenomenon, we recommend further studies to determine the association between PR/PR-LE and COVID-19 vaccination.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Cureus Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Cureus Year: 2022 Document Type: Article